Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:07 PM ET Form 4
Insider Selling Assurant, Inc. AIZ

Assurant EVP, Pres, Global Housing Ryan Lumsden Sells $1.25M of Stock

Ryan Lumsden, EVP, Pres, Global Housing, sold 3,901 shares of Assurant, Inc. at $319.37 a share, worth $1.25M in total on Nov 10, 2026. Shares held after the trade: 13,432 (-22.5%).

Value
$1.25M
Shares
3,901
Price
$319.37
Role
EVP, Pres, Global Housing
Holding change
-22.5%
Trade date
Nov 10, 2026
4:07 PM ET 8-K
Financial Results Journey Medical Corp DERM

Journey Medical Financial Results

Journey Medical Corporation reported third quarter 2026 financial results, featuring total revenues of $19.0 million, an 8% increase year-over-year. Growth was primarily driven by its oral rosacea treatment, Emrosi, which saw an 84% revenue increase to $9.0 million. The company's net loss narrowed to $1.3 million compared to $2.3 million in the prior-year period.

“We continued to make progress during the third quarter, delivering year-over-year revenue growth, a higher gross margin, and positive EBITDA. Third quarter sales of Emrosi®, our best-in-class oral rosacea treatment, increased by 84% compared to the prior-year period, driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans.”

Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer

“Building on this progress and with over $22 million in cash, we believe we are well-positioned to advance our mission of delivering value to our dermatology customers and their patients while building long-term shareholder value.”

Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer
4:07 PM ET 10-Q
Financial Results Fennec Pharmaceuticals Inc. FENC

Fennec Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $4.64M

Fennec Pharmaceuticals reported a significant increase in total revenue to $19.6 million for Q3 2026, driven by PEDMARK product sales. The company achieved net income of $4.6 million compared to a net loss in the prior year, supported by a decrease in G&A expenses and improved operating margins. Cash reserves stood at $48.7 million, which management expects will be sufficient to fund operations based on the current plan.

Key figure
Net income $4.64M
4:07 PM ET 10-Q
Financial Results Elite Pharmaceuticals Inc ELTP

Elite Pharmaceuticals Q2 2026 Results: Net Income $17.3M, Up 26.4% YoY

Elite Pharmaceuticals reported net income of $23.2 million for the six months ended September 30, 2026, a significant increase from $7.8 million in the prior year period, largely driven by a $9.8 million gain from the change in fair value of derivative warrants. While six-month revenue slightly decreased to $72.4 million, the company maintained a strong cash position of $34.9 million and significantly reduced its total liabilities from $39.4 million to $22.1 million.

Key figure
Net income $17.3M · +26.4% YoY
4:07 PM ET 10-Q
Financial Results Nuwellis, Inc. NUWE

Nuwellis Q3 2026 Results: Net Loss of $1.97M

Nuwellis, Inc. reported net sales of $6.58 million for the nine months ended September 30, 2026, a 12.6% increase over the prior year. Despite improved gross margins, the company incurred a net loss of $11.34 million, driven by higher operating expenses and significant financing-related costs, though this was an improvement from the $15.10 million loss in the same period of 2025.

Key figure
Net loss $1.97M
4:07 PM ET Form 4
Insider Selling Viasat Inc VSAT

Viasat CAO Camellia E. FitzGerald Sells $2.8M of Stock

Camellia E. FitzGerald, CAO, sold 37,500 shares of Viasat Inc at $74.55 a share, worth $2.8M in total on Nov 10, 2026. Shares held after the trade: 12,958 (-74.3%).

Value
$2.8M
Shares
37,500
Price
$74.55
Role
CAO
Holding change
-74.3%
Trade date
Nov 10, 2026
4:07 PM ET 10-Q
Financial Results Jerash Holdings (US), Inc. JRSH

Jerash Holdings Q2 2026 Results: Net Income $2.16M, Up 367.3% YoY

Jerash Holdings reported a significant increase in net income to $3.84 million for the six months ended September 30, 2026, compared to $0.80 million in the prior year period, driven by a 23% revenue growth to $100.5 million. The company maintained its quarterly dividend of $0.05 per share while seeing a substantial improvement in cash flow from operating activities, which rose to $7.53 million.

Key figure
Net income $2.16M · +367.3% YoY
4:07 PM ET 8-K
Financial Results Prime Medicine, Inc. PRME

Prime Medicine Financial Results

Prime Medicine reported Q3 2026 financial results, highlighting the first patient dosed in its Phase 1/2 trial for Wilson disease and FDA clearance for its AATD program. The company also completed a $143.7 million public offering, extending its cash runway through 2027.

Term
Q3 2026

“Prime Medicine continued to make significant progress this quarter, highlighted by dosing the first patient in our Phase 1/2 trial of PM577a for Wilson disease, our first clinical study of an in vivo Prime Editing therapy.”

Allan Reine, M.D., Chief Executive Officer

“Our recent financing strengthens our balance sheet and provides additional resources needed to advance these programs through key clinical milestones. Looking ahead, we expect 2027 to be a meaningful year for the patient communities we hope to treat, with initial clinical data anticipated from both PM577a and PM647 and a planned BLA submission for PM359.”

Allan Reine, M.D., Chief Executive Officer
4:07 PM ET 8-K
Financial Results Jefferson Capital, Inc. JCAP

Jefferson Capital Financial Results

Jefferson Capital reported record third-quarter 2026 results, with revenue climbing 23% to $185.5 million and net income reaching $46.9 million. The company saw significant growth in deployments, which rose 111% to $318.0 million, driven by triple-digit growth across its U.S., U.K., and Latin American platforms.

Term
Q3 2026

“Third quarter performance was excellent and we continue to build significant momentum in all key aspects of the business. We are confident in our ability to generate attractive shareholder returns in the near and long term.”

David Burton, Chairman and Chief Executive Officer

“We delivered the largest third quarter deployments in the Company’s history, with triple digit growth year-over-year in the United States, the United Kingdom and Latin America – a testament to our leadership position in hard-to-value and hard-to-service asset classes, the growing geographic breadth of our platform, and the strength of our client relationships.”

David Burton, Chairman and Chief Executive Officer
4:07 PM ET 8-K
Financial Results System1, Inc. SST

System1 Financial Results

System1 reported Q3 2026 revenue of $26.0 million and a GAAP net loss of $61.5 million, citing traffic and monetization headwinds from Google's AI overviews. Concurrent with the results, the company announced its intention to voluntarily delist its Class A common stock from the NYSE and transition to the OTC Venture Market to reduce costs.

“Our third quarter was challenging, as Google's AI overviews continued to siphon traffic from publishers and Google reduced monetization for independent search engines. We responded with a comprehensive strategic review of our businesses and a reallocation of resources to our offerings where AI is a tailwind. Our decision to move from the NYSE to the OTC Venture Market comes from the same discipline – lowering our costs and freeing our team to focus on growth initiatives.”

Michael Blend, System1’s Co-Founder & Chief Executive Officer

“Our third quarter results reflect continued pressure on Google monetization at Startpage and the loss of monetizable organic traffic to CouponFollow driven by Google displacing organic links with AI overviews on its search results pages. Our priority is maximizing cash flow and preserving liquidity while we invest selectively behind our highest-return opportunities.”

Tridivesh Kidambi, Chief Financial Officer of System1
4:07 PM ET 8-K
Financial Results Intrusion Inc INTZ

Intrusion Financial Results

Intrusion Inc. reported Q3 2026 revenue of $2.7 million, an 84% sequential increase driven by the first full quarter of contribution from the VigilAigent acquisition. The company implemented cost-reduction initiatives and completed a $4.0 million debt-for-equity exchange in October to improve its balance sheet and Nasdaq compliance status.

Term
Q3 2026

“Our third quarter results represent an important step forward for Intrusion as we continued to stabilize our business, integrate VigilAigent’s capabilities with our existing platform, and execute on our growth strategy.”

Tony Scott, President & Chief Executive Officer

“Our focus remains on growing recurring revenue, expanding our commercial reach, and continuing to build a stronger platform that delivers AI-driven cybersecurity solutions to address the evolving threats facing our customers across both commercial and government markets.”

Tony Scott, President & Chief Executive Officer
4:07 PM ET 8-K
Capacity Expansion Applied Optoelectronics, Inc. AAOI

Applied Optoelectronics Capacity Expansion: $102M Investment

Applied Optoelectronics completed the $102.25 million acquisition of three buildings at Hightower Business Park in Houston, Texas, totaling approximately 736,216 square feet. The company exercised purchase options in its existing leases to secure the facilities for manufacturing, warehouse, and office use, subsequently terminating the related lease agreements.

Value
$102M
Counterparty
Hightower Phase I Owner, LLC
4:07 PM ET 8-K
Leadership Change LQR House Inc. YHC

LQR House Leadership Change

Hon Kit Anthony Kwong resigned from the Board of Directors of LQR House Inc. effective November 12, 2026, with no reported disagreements. The Board appointed Ms. Huan Wang, an experienced finance professional, to fill the vacancy and serve as an independent director with an annual cash fee of $48,000.

4:07 PM ET 10-Q
Financial Results Fractyl Health, Inc. GUTS

Fractyl Health Q3 2026 Results: Net Loss of $14.2M, Loss Narrows

Fractyl Health reported a net loss of $30.5 million for the first nine months of 2026, a significant improvement from the $97.2 million loss in the prior year period, primarily driven by a $29.1 million gain from the change in fair value of warrant liabilities. The company implemented a strategic reprioritization in October 2026, including a workforce reduction, to extend its financial runway as cash and cash equivalents decreased to $31.5 million from $81.5 million at year-end 2025.

Key figure
Net loss $14.2M
4:07 PM ET 10-Q
Financial Results Pershing Square Sparc Holdings, Ltd.

Pershing Square Sparc Holdings Q3 2026 Results: Net Loss of $1.86M, Loss Widens

Pershing Square SPARC Holdings, Ltd. reported a net loss of $1.86 million for the quarter ended September 30, 2026, primarily driven by legal fees and a $1.77 million change in the fair value of Sponsor Warrants liability. The company remains a shell company focused on identifying a business combination, with $19.26 million in total cash and cash equivalents as of the period end.

Key figure
Net loss $1.86M
4:07 PM ET 10-Q
Financial Results Adial Pharmaceuticals, Inc. AZR

Azora Therapeutics Q3 2026 Results: Net Loss of $64.6M, Loss Widens

Azora Therapeutics, Inc. (formerly Adial Pharmaceuticals) reported a significant net loss of $118.6 million for the nine months ended September 30, 2026, primarily driven by a $46.2 million charge for acquired in-process R&D and a $48.8 million change in the fair value of milestone warrant rights. Following its acquisition of Legacy Azora in June 2026, the company's cash position increased to $22.0 million, supported by $26.8 million in proceeds from a private placement of pre-funded warrants.

Key figure
Net loss $64.6M
4:07 PM ET 10-Q
Financial Results Brightline Interactive, Inc. BTLN

Brightline Interactive Q1 2026 Results: Net Loss of $1.44M, Loss Widens

Brightline Interactive, Inc. reported a net loss of $1.44 million for the quarter ended September 30, 2026, compared to a $1.03 million loss in the prior year period. The company underwent a major restructuring in mid-2026, divesting most subsidiaries to focus on its SpatialCore platform, and has issued a going concern warning due to recurring losses and an accumulated deficit of $83.66 million.

Key figure
Net loss $1.44M
4:07 PM ET 10-Q
Financial Results Aei Income & Growth Fund Xxii Ltd Partnership XAEIU

Aei Income & Growth Fund Xxii Ltd Partnership Q3 2026 Results: Net Income $21.9K, Down 90.3% YoY

For the nine months ended September 30, 2026, the Partnership reported net income of $29,303, a significant decrease from $236,353 in the prior year period, primarily due to a $200,237 gain on real estate sales in 2025. The Managing General Partner has decided to begin the final liquidation process of the Partnership by disposing of its remaining assets.

Key figure
Net income $21.9K · -90.3% YoY
4:06 PM ET Form 4
Insider Selling Capital One Financial Corp COF

Capital One Financial Insider Peter E. Raskind Sells $256K of Stock

Peter E. Raskind sold 1,260 shares of Capital One Financial Corp at $203.00 a share, worth $256K in total on Nov 9, 2026. Shares held after the trade: 31,455 (-3.9%).

Value
$256K
Shares
1,260
Price
$203.00
Holding change
-3.9%
Trade date
Nov 9, 2026
4:06 PM ET Form 4
Insider Selling General Electric Co GE

General Electric Chairman and CEO H. Lawrence Culp Jr. Sells $2.7M of Stock

H. Lawrence Culp Jr., Chairman and CEO, sold 8,000 shares of General Electric Co at $337.25 to $338.29 a share (average $337.34) in 2 transactions, worth $2.7M in total on Nov 11, 2026. Shares held after the trade: 1,000,262 (-0.7%).

Value
$2.7M
Shares
8,000
Average price
$337.34
Role
Chairman and CEO
Holding change
-0.7%
Trade date
Nov 11, 2026
4:06 PM ET Form 4
Insider Selling Hershey Co HSY

Hershey Insider Hershey Trust Co Trustee in Trust for Milton Hershey School Sells $5.2M of Stock

Hershey Trust Co Trustee in Trust for Milton Hershey School sold 30,000 shares of Hershey Co at $170.69 to $176.90 a share (average $173.34) in 16 transactions, worth $5.2M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 386,119 (-0.5%).

Value
$5.2M
Shares
30,000
Average price
$173.34
Holding change
-0.5%
Trade date
Nov 9, 2026 to Nov 11, 2026
4:06 PM ET 10-Q
Financial Results BC Partners Lending Corp BCPL

BC Partners Lending Q3 2026 Results: Net Loss of $457K

BC Partners Lending Corp reported total investment income of $16.9 million for the nine months ended September 30, 2026, compared to $14.2 million in the prior year period. The company experienced a net decrease in net assets resulting from operations of $1.8 million for the nine-month period, primarily driven by $8.5 million in net realized and unrealized losses which offset $6.7 million in net investment income.

Key figure
Net loss $457K
4:06 PM ET 8-K
Financial Results Fractyl Health, Inc. GUTS

Fractyl Health Financial Results

Fractyl Health reported Q3 2026 financial results and announced a major strategic pivot to focus on its Revita program, including a 45% workforce reduction and the discontinuation of internal Rejuva development. The company reported positive six-month pivotal data from its REMAIN-1 trial and plans to submit an FDA De Novo marketing application in late Q4 2026.

Term
Q3 2026

“There are approximately 1 million Americans discontinuing GLP-1s each month, and these individuals are at high risk of weight and metabolic rebound. In this context, we believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl. In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance.”

Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer

“Armed with positive data, we have focused the Company around Revita’s post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut.”

Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
4:06 PM ET 8-K
Financial Results Candel Therapeutics, Inc. CADL

Candel Therapeutics Financial Results

Candel Therapeutics reported third quarter 2026 financial results, ending the period with $203.1 million in cash which is expected to fund operations into Q2 2028. The company updated its regulatory timeline, now planning to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in mid-2027 following assay refinement. Recent clinical progress included three poster presentations at the SITC 41st Annual Meeting showcasing data across its prostate, lung, and glioma programs.

Term
Q3 2026

“During the quarter we continued to execute well and make significant progress across the business, as we build the foundation to potentially become a commercial-stage biopharma company.”

Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO

“On the clinical side, we were honored to have had three posters accepted for presentation at SITC, featuring data on aglatimagene in localized prostate cancer and non-small cell lung cancer, and linoserpaturev in recurrent high-grade glioma. Together, the new biomarker data provide mechanistic support for the systemic effect and long-term clinical outcomes observed in our phase 3 trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer.”

Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO
4:06 PM ET 8-K
Financial Results BioStem Technologies, Inc. BSEM

BioStem Technologies Financial Results

BioStem Technologies reported Q3 2026 financial results, highlighting sequential hospital revenue growth to $6.8 million and increased customer penetration. The company raised its full-year 2026 revenue guidance and is finalizing a cost reduction plan to reduce annualized cash operating expenses by $10-$12 million.

Term
Q3 2026

“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines.”

Jason Matuszewski, Chair and CEO of BioStem

“With these foundations in place, we are focused on strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven.”

Jason Matuszewski, Chair and CEO of BioStem
4:06 PM ET 8-K
Financial Results Hour Loop, Inc HOUR

Hour Loop Financial Results

Hour Loop reported Q3 2026 financial results with net revenues of $32.1 million, a 4% decrease year-over-year, and net income of $0.4 million. The company narrowed its full-year 2026 guidance and highlighted its transition to an AI-first operating model to drive efficiency in purchasing and customer service.

Term
Q3 2026

“Through the first nine months of 2026, Hour Loop grew net revenues 11% and earned $2.3 million in net income, and we stayed profitable through a tougher third quarter. We made a deliberate choice to protect our margins rather than chase low-quality sales, and we believe that discipline puts us in a strong position as we head into the holiday season, the most important time of our year.”

Sam Lai, Chief Executive Officer and Interim Chief Financial Officer

“We are building an AI-first company, and AI is already changing how we work every day. AI agents now support core parts of our operations – purchasing and replenishment, advertising, pricing, inbound shipments, inventory reconciliation, customer service and compliance.”

Sam Lai, Chief Executive Officer and Interim Chief Financial Officer
4:06 PM ET 8-K
Financial Results Talphera, Inc. TLPH

Talphera Financial Results

Talphera reported a Q3 2026 net loss of $4.0 million and ended the quarter with $14.2 million in cash and investments. The company has submitted a briefing document to the FDA requesting to close enrollment for its pivotal NEPHRO CRRT study by year-end 2026, citing that current enrollment provides over 80% statistical power for the primary endpoint.

“We believe nafamostat has the potential to address an important unmet need as a regional anticoagulant for critically ill patients undergoing CRRT. Our updated market research, including physician feedback on nafamostat compared with currently used products, supports its potential adoption in CRRT and an increased peak sales estimate of more than $200 million.”

Vince Angotti, CEO of Talphera

“To date, we have enrolled more than 75% of the planned 70 patients. To support our goal of completing the study this year, we have submitted a briefing document to the FDA seeking feedback on closing enrollment as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled. While the study remains blinded and open for enrollment, we believe the current enrollment is sufficient to support a PMA filing as it has over 80% statistical power for the primary endpoint.”

Vince Angotti, CEO of Talphera
4:06 PM ET Form 4
Insider Selling LuxExperience B.V. LUXE

LuxExperience B.V CEO Michael Kliger Sells $400K of Stock

Michael Kliger, CEO, sold 38,412 shares of LuxExperience B.V. at $10.41 a share, worth $400K in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).

Value
$400K
Shares
38,412
Price
$10.41
Role
CEO
Holding change
-100.0%
Trade date
Nov 10, 2026
4:06 PM ET Form 4
Insider Buying Alnylam Pharmaceuticals, Inc. ALNY

Alnylam Pharmaceuticals Insider Charles Elliott Sigal Buys $244K of Stock

Charles Elliott Sigal bought 1,600 shares of Alnylam Pharmaceuticals, Inc. at $152.25 a share, worth $244K in total on Nov 10, 2026. Shares held after the trade: 3,600 (+80.0%).

Value
$244K
Shares
1,600
Price
$152.25
Holding change
+80.0%
Trade date
Nov 10, 2026
4:06 PM ET 8-K
M&A Deal GoPro, Inc. GPRO

GoPro M&A Deal with Action Acquisition LLC

GoPro entered into an amendment to its existing merger agreement with Action Acquisition LLC, extending the deal's outside closing date from December 31, 2026, to March 31, 2027. The amendment also includes technical adjustments for potential stock splits or reclassifications and corrects a scrivener's error regarding the parent company's name. Parent is required to seek an extension of its financing commitment letter to match the new March 2027 deadline.

Counterparty
Action Acquisition LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.